DelveInsight’s 'Complement Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline complement inhibitors in various stages of clinical development, major ...
Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
The serum complement system, which represents a chief component of innate immunity, not only participates in inflammation but also acts to enhance the adaptive immune response. Specific activation of ...
(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results